Vaishali Pharma Limited
NSE:VAISHALI.NS
192.25 (INR) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 862.797 | 696.628 | 715.368 | 523.077 | 584.114 | 724.555 | 654.98 | 660.548 | 667.072 | 945.606 | 1,207.082 | 1,188.1 |
| Cost of Revenue
| 772.474 | 546.776 | 635.006 | 461.515 | 510.89 | 686.62 | 599.008 | 574.203 | 620.331 | 912.511 | 1,142.213 | 1,135.513 |
| Gross Profit
| 90.323 | 149.852 | 80.362 | 61.562 | 73.224 | 37.935 | 55.972 | 86.345 | 46.741 | 33.095 | 64.869 | 52.587 |
| Gross Profit Ratio
| 0.105 | 0.215 | 0.112 | 0.118 | 0.125 | 0.052 | 0.085 | 0.131 | 0.07 | 0.035 | 0.054 | 0.044 |
| Reseach & Development Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 5.466 | 3.775 | 4.18 | 2.613 | 3.436 | 2.681 | 7.284 | 23.865 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 4.859 | 5.292 | 26.732 | 8.832 | 10.735 | 10.703 | 13.23 | 2.98 | 0 | 0 | 0 | 0 |
| SG&A
| 84.029 | 9.067 | 30.913 | 11.444 | 14.17 | 13.385 | 20.514 | 26.845 | 25.698 | 18.454 | 20.024 | 11.949 |
| Other Expenses
| 3.839 | 22.287 | 0.473 | 1.524 | 12.758 | 0.096 | 0.018 | 10.574 | 31.841 | 42.631 | 8.608 | 2.885 |
| Operating Expenses
| 84.029 | 63.601 | 16.071 | 21.144 | 26.928 | 20.044 | 28.993 | 55.572 | 44.942 | 40.514 | 40.58 | 37.23 |
| Operating Income
| 6.294 | 88.738 | 64.29 | 22.211 | 4.628 | 17.891 | 26.979 | 30.773 | 1.799 | -7.419 | 24.289 | 15.357 |
| Operating Income Ratio
| 0.007 | 0.127 | 0.09 | 0.042 | 0.008 | 0.025 | 0.041 | 0.047 | 0.003 | -0.008 | 0.02 | 0.013 |
| Total Other Income Expenses Net
| 2.967 | -0.276 | -7.006 | -8.166 | -3.837 | -6.567 | -13.524 | -20.644 | -1.835 | 8.936 | -18.147 | -6.472 |
| Income Before Tax
| 9.261 | 88.453 | 57.284 | 14.045 | 0.791 | 11.325 | 13.455 | 10.129 | -0.036 | 1.517 | 6.142 | 8.885 |
| Income Before Tax Ratio
| 0.011 | 0.127 | 0.08 | 0.027 | 0.001 | 0.016 | 0.021 | 0.015 | -0 | 0.002 | 0.005 | 0.007 |
| Income Tax Expense
| 2.072 | 22.424 | 17.047 | 3.583 | 0.463 | 4.189 | 5.479 | 3.491 | 0.267 | -0.097 | 3.137 | 2.886 |
| Net Income
| 7.189 | 66.035 | 40.237 | 10.463 | 0.328 | 7.136 | 7.976 | 6.637 | -0.303 | 1.615 | 3.005 | 6 |
| Net Income Ratio
| 0.008 | 0.095 | 0.056 | 0.02 | 0.001 | 0.01 | 0.012 | 0.01 | -0 | 0.002 | 0.002 | 0.005 |
| EPS
| 0.67 | 6.26 | 3.82 | 0.99 | 0.03 | 0.68 | 0.88 | 0.67 | -0.029 | 0.15 | 0.28 | 0.57 |
| EPS Diluted
| 0.64 | 5.91 | 3.82 | 0.99 | 0.03 | 0.68 | 0.88 | 0.67 | -0.029 | 0.15 | 0.28 | 0.57 |
| EBITDA
| 11.375 | 113.582 | 86.735 | 62.778 | 72.406 | 40.13 | 44.528 | 43.846 | 37.315 | 39.742 | 33.338 | 18.584 |
| EBITDA Ratio
| 0.013 | 0.163 | 0.121 | 0.12 | 0.124 | 0.055 | 0.068 | 0.066 | 0.056 | 0.042 | 0.028 | 0.016 |